Taurochenodeoxycholic Acid: A Novel Metabolic Sentinel Reversing Obesity-Induced Endothelial Dysfunction via the FXR-PHB1-ATF4 Axis
Posted inCardiology Diabetes & Endocrinology news

Taurochenodeoxycholic Acid: A Novel Metabolic Sentinel Reversing Obesity-Induced Endothelial Dysfunction via the FXR-PHB1-ATF4 Axis

This study identifies TCDCA as a key metabolite that restores endothelial function in obesity. By activating the endothelial FXR-PHB1-ATF4 pathway, TCDCA enhances serine metabolism, offering a promising therapeutic strategy to mitigate cardiovascular risk in obese populations.
Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes
Posted inClinical Updates Diabetes & Endocrinology news

Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes

This review synthesizes the landmark RADIANT trial findings, demonstrating the efficacy of transitioning patients from multiple daily injections to tubeless automated insulin delivery, while integrating broader evidence on genetic susceptibility and metabolic comorbidity management.
Beyond Haploinsufficiency: How Nonsense-Mediated Decay Escape Redefines MODY Diagnosis and Identifies Novel INS Variants
Posted inDiabetes & Endocrinology news

Beyond Haploinsufficiency: How Nonsense-Mediated Decay Escape Redefines MODY Diagnosis and Identifies Novel INS Variants

A systematic analysis reveals that the pathogenicity of loss-of-function variants in MODY genes is gene-specific and dependent on nonsense-mediated decay status. Crucially, NMD-escape variants in the INS gene represent a novel, clinically distinct cause of MODY, improving diagnostic precision for monogenic diabetes.
Precision Risk Stratification in Cushing’s Disease: Integrating USP8 Genotype and Tumor Size to Predict Long-Term Recurrence
Posted inDiabetes & Endocrinology news

Precision Risk Stratification in Cushing’s Disease: Integrating USP8 Genotype and Tumor Size to Predict Long-Term Recurrence

An international cohort study demonstrates that combining USP8 genotype with tumor size significantly improves the prediction of recurrence in Cushing's disease, identifying high-risk patients even among those with low postoperative cortisol levels, paving the way for personalized long-term follow-up.